TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03927131

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVV-IB
Description: Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVY-IB
Description: Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot A
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot B
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB Lot C
Description: Inactivated split-virion quadrivalent influenza vaccine - Lot C
Study: NCT04930549

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo tablets once a day during 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: impedance cardiography
Description: impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: impedance cardiography
Description: impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applanation tonometry
Description: Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Applanation tonometry
Description: Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-ischemic hyperemia of forearm
Description: An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: post-ischemic hyperemia of forearm
Description: An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodynamics parameters
Description: haemodynamics parameters will be evaluated using automatic oscillometric recorder

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: haemodynamics parameters
Description: haemodynamics parameters will be evaluated using automatic oscillometric recorder
Study: NCT06542601

Intervention type: DEVICE
Intervention: Motor cognitive intervention
Description: Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
Study: NCT06510504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225 mg BNC210
Description: 225 mg BNC210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05407467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin and virgin coconut oil extract (KurCo Smart)
Description: we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
Study: NCT06374706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Walk training for stroke
Description: Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning Walk training for healthy
Description: Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
Study: NCT05168488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted morning resistance exercise
Description: On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Afternoon resistance exercise
Description: On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
Study: NCT05183373

Intervention type: OTHER
Intervention: Evaluation of inflammation and clotting
Description: Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)

Intervention type: OTHER
Intervention: Evaluation of inflammation and clotting
Description: Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)

Intervention type: OTHER
Intervention: Evaluation of inflammation and clotting
Description: Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
Study: NCT06508658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion
Study: NCT05514938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (individual medications prescribed by primary cardiologist)
Description: Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
Study: NCT06560554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented foods
Description: Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No information on incorporation of fermented foods will be provided for subjects in the control arm.
Study: NCT05579626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity statin arm
Description: •high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity statin plus ezetimibe
Description: •low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
Study: NCT05690711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS8179
Description: HRS8179 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline
Study: NCT04142866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: 2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: 2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-Language Therapy (SLT)
Description: Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
Study: NCT05802667

Intervention type: DIAGNOSTIC_TEST
Intervention: Tryptase
Description: Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
Study: NCT05744544

Intervention type: PROCEDURE
Intervention: External Oblique Block
Description: Patients will be followed after EOIB which are routinely performed in our clinic.

Intervention type: PROCEDURE
Intervention: m-TAPA block
Description: m-TAPA block
Study: NCT04682067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Escalating financial incentives contingent upon biochemical evidence of abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care smoking cessation
Description: Usual care smoking cessation support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care smoking cessation
Description: Usual care smoking cessation support
Study: NCT04142866

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech-Language Therapy (SLT)
Description: Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
Study: NCT04920604

Intervention type: OTHER
Intervention: Face-to-face anesthesia consultation
Description: The anesthesia consultation is carried out in person in accordance with the usual management.

Intervention type: OTHER
Intervention: Remote anesthesia consultation
Description: Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation.
Study: NCT06287593

Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA monitoring
Description: Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.

Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA monitoring
Description: Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.

Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA monitoring
Description: Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.

Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA monitoring
Description: Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
Study: NCT05891886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather mask
Description: Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-rebreather mask
Description: Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
Study: NCT06035393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2005 inhalation
Description: Drug 1: dose 1; dose 2; dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2005 inhalation
Description: Drug 1: dose 1; dose 2; dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2005 inhalation
Description: Drug 1: dose 1; dose 2; dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match HRG2005 inhalation
Description: Drug 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match HRG2005 inhalation
Description: Drug 2

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to match HRG2005 inhalation
Description: Drug 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Description: Drug 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Description: Drug 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Description: Drug 3

Intervention type: DRUG
Group type: OTHER
Intervention: Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Description: Drug 4
Study: NCT06209593

Intervention type: DIETARY_SUPPLEMENT
Intervention: Compleat plant protein tube feed
Description: Patients on a tube feed will act as their own control and switch to new tube feed.
Study: NCT05615675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Patient uses a virtual reality headset and support during prone pain procedure
Study: NCT05727176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 is an oral FGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 is an oral FGFR inhibitor
Study: NCT06492382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home Oxygen Monitors
Description: Weaning of home oxygen using information gathered from home moniotr devise

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home Oxygen Monitors
Description: Weaning of home oxygen using information gathered from home moniotr devise
Study: NCT06026969

Intervention type: OTHER
Intervention: Neurodevelopmental assessments and follow-up
Description: All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.

Intervention type: OTHER
Intervention: Neurodevelopmental assessments and follow-up
Description: All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
Study: NCT05129904

Intervention type: OTHER
Intervention: Double plasma molecular absorption system
Description: DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
Study: NCT05699993

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Itraconazole was administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 was administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 was administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan was administered orally
Study: NCT04420572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone injection
Description: ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Description: 1ml betamethasone will be used for steroid injection.
Study: NCT05352308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Sense Model Guided Narrative Video
Description: The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
Study: NCT06274099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nursing care
Description: It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing care
Description: It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
Study: NCT05440058

Intervention type: DEVICE
Intervention: Bispectral Index (BIS) monitoring system
Description: Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
Study: NCT05136794

Intervention type: OTHER
Intervention: Data collection
Description: complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay

Intervention type: OTHER
Intervention: Data collection
Description: complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
Study: NCT06039436

Intervention type: DRUG
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
Study: NCT06597266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart template - designed prosthetic check socket
Description: Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart template - designed prosthetic check socket
Description: Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinician-designed prosthetic check socket
Description: Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinician-designed prosthetic check socket
Description: Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
Study: NCT06596954

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: lymphocyte-sparing radiotherapy
Description: the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy
Description: the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
Study: NCT06356935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RT
Description: Resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: Control group
Study: NCT06606184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle Training
Description: Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Routine Care
Description: Participants received routine care, which included encouragement to use incentive spirometry three times daily.
Study: NCT06605352

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The BIOFIRE®FILMARRAY® Pneumonia Panel
Description: The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection.